|
EP0901786B1
(en)
|
1997-08-11 |
2007-06-13 |
Pfizer Products Inc. |
Solid pharmaceutical dispersions with enhanced bioavailability
|
|
RU2222329C2
(ru)
*
|
1998-04-24 |
2004-01-27 |
Скариста Лимитед |
Лечение депрессии и фармацевтические препараты для этой цели
|
|
CZ20004279A3
(cs)
*
|
1998-05-22 |
2001-09-12 |
Eli Lilly And Company |
Lék pro léčení nepoddajné deprese a farmaceutická kompozice
|
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
|
CZ20004280A3
(cs)
*
|
1998-05-29 |
2001-09-12 |
Eli Lilly And Company |
Lék pro léčbu bipolárních poruch a farmaceutický prostředek
|
|
AU1321900A
(en)
*
|
1998-10-23 |
2000-05-15 |
Sepracor, Inc. |
Compositions and methods employing r(-) fluoxetine and other active ingredients
|
|
CA2352611A1
(en)
*
|
1998-11-23 |
2000-06-02 |
Sepracor Inc. |
2-hydroxymethylolanzapine compositions and methods
|
|
EP1027885B1
(en)
*
|
1999-02-09 |
2008-07-09 |
Pfizer Products Inc. |
Basic drug compositions with enhanced bioavailability
|
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
CA2367402C
(en)
|
1999-03-12 |
2010-11-23 |
Basf Aktiengesellschaft |
Stable pharmaceutical dosage form for paroxetine anhydrate
|
|
JP2002544223A
(ja)
*
|
1999-05-12 |
2002-12-24 |
ソルベイ・フアーマシユーチカルズ・ベー・ブイ |
精神病性障害の治療方法
|
|
CA2363784A1
(en)
*
|
1999-05-19 |
2000-11-30 |
Astrazeneca Ab |
Method of treatment
|
|
AU4973800A
(en)
*
|
1999-06-09 |
2000-12-28 |
Eli Lilly And Company |
Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
|
|
AR021155A1
(es)
*
|
1999-07-08 |
2002-06-12 |
Lundbeck & Co As H |
Tratamiento de desordenes neuroticos
|
|
CA2385749A1
(en)
*
|
1999-09-28 |
2001-04-05 |
H. Lundbeck A/S |
Melt granulated composition and modified release dosage form prepared from said composition
|
|
AU3789901A
(en)
|
1999-12-17 |
2001-06-25 |
Bristol-Myers Squibb Company |
Antipsychotic heterocycle compounds
|
|
JP2003518485A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
向上された薬物濃度を与える医薬組成物
|
|
US6572890B2
(en)
*
|
2000-01-13 |
2003-06-03 |
Osmotica Corp. |
Osmotic device containing venlafaxine and an anti-psychotic agent
|
|
AU2001268055A1
(en)
*
|
2000-06-30 |
2002-01-14 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
US7666445B2
(en)
*
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
|
US20030232881A1
(en)
*
|
2000-10-27 |
2003-12-18 |
H. Lundbeck A/S |
Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
|
|
CA2364211A1
(en)
*
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
|
EP1353675A2
(en)
*
|
2001-01-02 |
2003-10-22 |
PHARMACIA & UPJOHN COMPANY |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
|
WO2002062346A1
(en)
*
|
2001-02-06 |
2002-08-15 |
Astrazeneca Ab |
Method of treating substance abuse with quetiapine
|
|
US20020123490A1
(en)
*
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
|
KR20040030609A
(ko)
*
|
2001-05-01 |
2004-04-09 |
하. 룬트벡 아크티에 셀스카브 |
경상이성체성 순수 에스시탈로프람의 용도
|
|
US7034059B2
(en)
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
|
WO2004010932A2
(en)
*
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
KR100842694B1
(ko)
|
2002-12-27 |
2008-07-01 |
오쓰까 세이야꾸 가부시키가이샤 |
기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
|
|
AR042806A1
(es)
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
|
MXPA05012391A
(es)
*
|
2003-05-16 |
2006-02-02 |
Pfizer Prod Inc |
Tratamiento de trastornos psicoticos y depresivos.
|
|
WO2004100956A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
|
JP2007522095A
(ja)
*
|
2003-05-16 |
2007-08-09 |
ファイザー・プロダクツ・インク |
ジプラシドンを用いた不安の治療
|
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
|
US20050032781A1
(en)
*
|
2003-08-06 |
2005-02-10 |
Elliot Ehrich |
Methods for administering active agents to CYP 2D6 sensitive patients
|
|
PL1708790T3
(pl)
|
2003-12-02 |
2010-10-29 |
Pharmaneuroboost N V |
Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
|
|
US7884096B2
(en)
|
2003-12-02 |
2011-02-08 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
EP1547650A1
(en)
*
|
2003-12-02 |
2005-06-29 |
B & B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
WO2005053703A1
(en)
|
2003-12-02 |
2005-06-16 |
Leslie James Sheldon |
Combination therapy for dementia, depression and apathy
|
|
US7855195B2
(en)
|
2003-12-02 |
2010-12-21 |
Pharmaneuroboost N.V. |
Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
CA2550650A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
|
JP5306599B2
(ja)
*
|
2004-01-12 |
2013-10-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
長期間送達製剤
|
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
|
US7829700B2
(en)
|
2004-09-06 |
2010-11-09 |
Shasun Chemicals And Drugs Limited |
Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
|
|
EP1830844A1
(en)
*
|
2004-12-27 |
2007-09-12 |
Alpha 2 Pharmaceutical AB |
Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
|
|
CZ200563A3
(cs)
*
|
2005-02-02 |
2006-10-11 |
Zentiva, A. S. |
Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
|
|
UA97349C2
(uk)
*
|
2005-09-08 |
2012-02-10 |
Х. Луннбэк А/С |
Стійкі тверді склади сертиндолу
|
|
US20070093471A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals, Llc |
Compositions and methods for the administration clozapine formulations which modulate body weight
|
|
US9095519B2
(en)
*
|
2007-02-09 |
2015-08-04 |
Alphapharm Pty Ltd |
Dosage form containing two or more active pharmaceutical ingredients in different physical forms
|
|
WO2008122019A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Cypress Biosciences, Inc. |
Improving the tolerability of both mirtazapine and reboxetine by using them in combination
|
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
|
RU2508106C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
|
|
RU2508096C2
(ru)
*
|
2007-08-01 |
2014-02-27 |
Сергей Олегович Бачурин |
Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
|
|
JP5460594B2
(ja)
*
|
2007-08-03 |
2014-04-02 |
リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ |
ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法
|
|
EP2240173A4
(en)
*
|
2008-01-25 |
2013-07-17 |
Alphapharm Pty Ltd |
PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
|
|
WO2011018801A2
(en)
*
|
2009-08-12 |
2011-02-17 |
Genepharm India Pvt Ltd |
Solid oral dosage form of ziprasidone
|
|
EP2496079A4
(en)
*
|
2009-11-06 |
2014-05-14 |
Pierre Fabre Médicament Sas |
NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
|
|
EP3610890A1
(en)
|
2012-11-14 |
2020-02-19 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
US20160310524A1
(en)
*
|
2013-12-13 |
2016-10-27 |
Ralph Ankenman |
Compositions and methods for treating dysregulated systems
|
|
JP6718376B2
(ja)
|
2014-02-07 |
2020-07-08 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
|
|
HUE053872T2
(hu)
|
2015-10-30 |
2021-07-28 |
Neurocrine Biosciences Inc |
Valbenazin-ditozilát és polimorfjai
|
|
MA44127A
(fr)
|
2015-12-23 |
2018-10-31 |
Neurocrine Biosciences Inc |
Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
|
|
US10336679B2
(en)
*
|
2016-10-24 |
2019-07-02 |
Syneurx International (Taiwan) Corp. |
Polymorphic forms of sodium benzoate and uses thereof
|
|
KR20200066662A
(ko)
|
2017-01-27 |
2020-06-10 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
IL309802A
(en)
|
2017-09-21 |
2024-02-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
|
MY198713A
(en)
|
2017-10-10 |
2023-09-19 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
CN108938645A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种抗精神病药物组合物
|
|
CN108938635A
(zh)
*
|
2018-08-24 |
2018-12-07 |
山西医科大学第医院 |
一种低剂量非典型抗精神病药物组合物
|
|
CN108926569A
(zh)
*
|
2018-08-24 |
2018-12-04 |
山西医科大学第医院 |
一种非典型抗精神病药物组合物
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN111084778B
(zh)
*
|
2019-12-31 |
2022-06-24 |
北京鑫开元医药科技有限公司 |
一种奥氮平盐酸氟西汀胶囊及其制备方法
|